Skip to main content

Table 2 Relationship between NLRs and clinical factors

From: An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer

Factor

pNLR (+)

pNLR (−)

P-value

iNLR (+)

iNLR (−)

P-value

fNLR (+)

fNLR (−)

P-value

Sex (M/F)

34/16

39/11

0.368

23/ 3

50/24

0.043

28/10

45/17

1.000

Age (< 65/≥65 years)

21/29

20/30

1.000

11/15

30/44

0.875

16/22

25/37

1.000

Tumor size (< 60/≥60 mm)

20/30

28/22

0.161

14/12

34/40

0.504

16/22

32/30

0.412

Histologic type (Diff/Undiff)

15/35

20/30

0.402

8/18

27/47

0.644

11/27

24/38

0.390

pT (1/2/3/4)

1/ 6/18/25

4/ 6/23/17

0.275

2/ 4/10/10

3/ 8/31/32

0.731

2/ 7/11/18

3/ 5/30/24

0.180

pN (0/1/2/3)

4/11/14/21

10/14/17/ 9

0.045

2/11/ 9/ 4

12/14/22/26

0.056

3/ 9/14/12

11/16/17/18

0.510

pStage (II/III)

13/37

26/24

0.013

12/14

27/47

0.484

15/23

24/38

1.000

Lymphatic invasion (+/−)

43/ 7

37/13

0.211

21/ 5

59/15

1.000

28/10

52/10

0.303

Venous invasion (+/−)

40/10

38/12

0.810

20/ 6

58/16

1.000

30/ 8

48/14

1.000

Recurrence (+/−)

22/28

13/37

0.093

9/17

26/48

1.000

24/14

11/51

< 0.001*

Outcome (D/A)

17/33

7/43

0.034

8/18

16/58

0.425

18/20

6/56

< 0.001*

  1. M, male; F, female; Diff, differentiated type; Undiff, undifferentiated type; pT, pN, pStage = pathological T stage, N stage. Pathological cancer stage according to the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual; pNLR, preoperative neutrophil-to-lymphocyte ratio; iNLR, the ratio of the NLR on the initial day of adjuvant chemotherapy to the pNLR; fNLR, the ratio of the NLR on the final day of adjuvant chemotherapy to the iNLR; D/A, dead or alive; *P-value indicates statistical significance after false discovery rate correction
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us